Brain Targeting and Aβ Binding Bifunctional Nanoparticles Inhibit Amyloid Protein Aggregation in APP/PS1 Transgenic Mice

Alzheimer’s disease (AD) is an insidious and progressive neurodegenerative disease with few disease-modifying treatments. A variety of peptide/protein drugs have neuroprotective effects, which brings new hope for the treatment of AD. However, the application of these drugs is limited because of thei...

Full description

Saved in:
Bibliographic Details
Published inACS chemical neuroscience Vol. 12; no. 12; pp. 2110 - 2121
Main Authors Zhang, Xiancheng, Zhang, Xiaoyu, Li, You, Zhong, Manli, Zhao, Pu, Guo, Chuang, Xu, He, Wang, Tao, Gao, Huiling
Format Journal Article
LanguageEnglish
Published American Chemical Society 16.06.2021
Subjects
β-amyloid peptide
Alzheimer’s disease
phage display peptide
bifunctional nanoparticles
brain targeting
Online AccessGet full text

Cover

Abstract Alzheimer’s disease (AD) is an insidious and progressive neurodegenerative disease with few disease-modifying treatments. A variety of peptide/protein drugs have neuroprotective effects, which brings new hope for the treatment of AD. However, the application of these drugs is limited because of their low specificity and difficulty in crossing the blood–brain barrier. Herein, using the phage display technology, we identified the Aβ oligomer binding peptide (KH) and the brain targeting peptide (IS). We combined these peptides to develop a bifunctional nanoparticle (IS@NP/KH) for the delivery of Aβ1–42 oligomer binding peptide into the brain. Intranasal administration of IS@NP/KH significantly attenuated the cognitive and behavioral deficits and reduced the Aβ deposition in the brain of an AD animal model (APPswe/PS 1d9 double-transgenic mice). Our results suggest that intranasal IS@NP/KH administration could be a novel therapeutic strategy for the treatment of AD.
AbstractList Alzheimer’s disease (AD) is an insidious and progressive neurodegenerative disease with few disease-modifying treatments. A variety of peptide/protein drugs have neuroprotective effects, which brings new hope for the treatment of AD. However, the application of these drugs is limited because of their low specificity and difficulty in crossing the blood–brain barrier. Herein, using the phage display technology, we identified the Aβ oligomer binding peptide (KH) and the brain targeting peptide (IS). We combined these peptides to develop a bifunctional nanoparticle (IS@NP/KH) for the delivery of Aβ1–42 oligomer binding peptide into the brain. Intranasal administration of IS@NP/KH significantly attenuated the cognitive and behavioral deficits and reduced the Aβ deposition in the brain of an AD animal model (APPswe/PS 1d9 double-transgenic mice). Our results suggest that intranasal IS@NP/KH administration could be a novel therapeutic strategy for the treatment of AD.
Author Xu, He
Zhong, Manli
Zhang, Xiancheng
Guo, Chuang
Gao, Huiling
Wang, Tao
Li, You
Zhao, Pu
Zhang, Xiaoyu
AuthorAffiliation Key Laboratory of Data Analytics and Optimization for Smart Industry
Department of Histology and Embryology, School of Medicine
College of Life and Health Sciences
Chinese Academy of Sciences
Northeastern University, Ministry of Education
Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics
AuthorAffiliation_xml – name: Department of Histology and Embryology, School of Medicine
– name: College of Life and Health Sciences
– name: Northeastern University, Ministry of Education
– name: Key Laboratory of Data Analytics and Optimization for Smart Industry
– name: Chinese Academy of Sciences
– name: Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics
Author_xml – sequence: 1
  givenname: Xiancheng
  surname: Zhang
  fullname: Zhang, Xiancheng
  organization: Chinese Academy of Sciences
– sequence: 2
  givenname: Xiaoyu
  surname: Zhang
  fullname: Zhang, Xiaoyu
  email: zhangxiaoyu@dicp.ac.cn
  organization: Chinese Academy of Sciences
– sequence: 3
  givenname: You
  surname: Li
  fullname: Li, You
  organization: College of Life and Health Sciences
– sequence: 4
  givenname: Manli
  surname: Zhong
  fullname: Zhong, Manli
  organization: College of Life and Health Sciences
– sequence: 5
  givenname: Pu
  surname: Zhao
  fullname: Zhao, Pu
  organization: College of Life and Health Sciences
– sequence: 6
  givenname: Chuang
  surname: Guo
  fullname: Guo, Chuang
  organization: College of Life and Health Sciences
– sequence: 7
  givenname: He
  surname: Xu
  fullname: Xu, He
  organization: Department of Histology and Embryology, School of Medicine
– sequence: 8
  givenname: Tao
  surname: Wang
  fullname: Wang, Tao
  organization: College of Life and Health Sciences
– sequence: 9
  givenname: Huiling
  orcidid: 0000-0002-5453-5882
  surname: Gao
  fullname: Gao, Huiling
  email: gaohuiling@mail.neu.edu.cn
  organization: Northeastern University, Ministry of Education
BookMark eNp9kE1uwjAQha2qlQq0N-jCy24CdhyHeBlQf5BoG6l0HRlnEowSm9rJgmv1ID1TE8GCVVczT_Pek-Ybo2tjDSD0QMmUkpDOpPJqB42BztkpVYQQxq_QiIooCeZUsOuL_RaNvd8TEguSxCN0XDipDd5IV0GrTYWlKXD6-4MX2hSDXuiyM6rV1sgav0tjD9K1WtXg8crs9Fa3OG2OtdUFzpxtoS9Lq8pBJYcMHmSWzbJPijdOGl-B0Qq_aQV36KaUtYf785ygr-enzfI1WH-8rJbpOpAs5G0A23khQSRQckYKHka8UJTHLAlZGQ4PCZpwRSURhHIFTMQ8jiXjxZxEjMGWTdDjqffg7HcHvs0b7RXUtTRgO5-HnDFGBWGit0Ynq3LWewdlfnC6ke6YU5IPpPNL0vmZdB8jp1h_zfe2cz0q_3_kD5XSiCs
CitedBy_id crossref_primary_10_1021_acs_analchem_1c02459
crossref_primary_10_1016_j_ijbiomac_2023_126821
crossref_primary_10_1038_s41570_023_00493_y
crossref_primary_10_1021_accountsmr_1c00193
crossref_primary_10_3390_molecules29133002
crossref_primary_10_3390_ijms22136842
crossref_primary_10_1016_j_ccr_2023_215375
crossref_primary_10_1007_s12033_024_01195_6
crossref_primary_10_1021_acschemneuro_2c00202
crossref_primary_10_3390_cells12232669
crossref_primary_10_1126_sciadv_ade0293
crossref_primary_10_1007_s11418_024_01825_y
crossref_primary_10_1021_acsanm_3c04846
crossref_primary_10_1021_acsabm_2c00771
crossref_primary_10_1088_1361_6528_ac85f3
crossref_primary_10_3390_ijms241713110
crossref_primary_10_1007_s00702_021_02431_y
Cites_doi 10.3390/pharmaceutics10020040
10.1111/j.1601-183X.2008.00453.x
10.1016/j.jocn.2019.01.003
10.1096/fj.05-5186fje
10.1039/C9BM00676A
10.3390/jcm9113452
10.1007/s13238-019-0639-7
10.1002/cmdc.200800273
10.1007/s11095-010-0053-6
10.1016/S0378-5173(01)00760-8
10.1039/D0CC01551B
10.1038/nrdp.2015.56
10.1002/anie.200802808
10.1016/S1389-0344(01)00087-9
10.1271/bbb.110879
10.1016/j.phymed.2020.153353
10.1038/nbt1193
10.1002/advs.201901165
10.1038/s41582-018-0116-6
10.1021/cr960065d
10.3233/JAD-151024
10.1016/j.cell.2019.09.001
10.1016/j.jneumeth.2016.04.026
10.1021/nn501292z
10.1271/bbb.100388
10.1038/380364a0
10.1007/s10856-017-5859-x
10.1016/j.npep.2015.06.008
10.1016/j.biomaterials.2011.03.031
10.1016/0006-8993(85)90963-1
10.1016/j.ejphar.2017.09.043
10.15252/emmm.201606666
10.1016/j.jconrel.2018.05.011
10.1016/j.ijpharm.2005.01.042
10.1016/j.bbrep.2020.100792
10.1007/s11095-013-1055-y
10.3791/838
10.1021/acsami.5b05606
10.1111/jnc.15007
10.1038/nm0202-121
10.1016/j.phrs.2004.05.005
10.1074/jbc.M113.537472
10.1038/nrm2101
10.4172/2161-0460.1000314
10.1016/j.brainres.2016.01.028
10.1038/emboj.2010.211
10.1039/D0SC02212H
10.1016/j.ijpharm.2019.02.012
10.1021/acschembio.7b00087
10.1016/j.neulet.2013.08.058
10.1073/pnas.072027199
10.1074/jbc.M111.264473
10.1016/j.ejps.2011.11.015
10.1002/adma.202006483
10.1038/nn.3028
10.1016/j.ebiom.2016.03.035
10.1073/pnas.0436286100
10.1073/pnas.1700407114
10.1002/anie.202002783
10.1002/psc.2789
10.1007/s00726-011-0979-y
10.1371/journal.pone.0147470
10.1111/j.1365-2990.2010.01137.x
10.1038/s41467-017-01096-0
10.1007/s12035-017-0487-5
10.3390/molecules25040874
10.1007/s11095-013-1025-4
10.1016/j.ejpb.2019.10.003
10.1021/acschemneuro.0c00518
ContentType Journal Article
Copyright 2021 American Chemical Society
Copyright_xml – notice: 2021 American Chemical Society
DBID AAYXX
CITATION
7X8
DOI 10.1021/acschemneuro.1c00035
DatabaseName CrossRef
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1948-7193
EndPage 2121
ExternalDocumentID 10_1021_acschemneuro_1c00035
c032755675
GroupedDBID -
3RI
53G
55A
5VS
7~N
AABXI
AAKDD
ABFRP
ABMVS
ABUCX
ACGFS
ACS
ADBBV
AEESW
AENEX
AFEFF
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAWUL
DIK
EBS
ED
ED~
F5P
GGK
GNL
GX1
IH9
JG
JG~
OK1
RNS
ROL
RPM
UI2
VF5
VG9
W1F
---
6J9
AAYXX
ABJNI
ABQRX
ACGFO
ADHLV
BAANH
CITATION
CUPRZ
7X8
ID FETCH-LOGICAL-a325t-eb7dae98ef530d5245dc1563823f271939185c1a09015ce396566a35d70433eb3
IEDL.DBID ACS
ISSN 1948-7193
IngestDate Fri Aug 16 04:16:51 EDT 2024
Fri Aug 23 03:15:03 EDT 2024
Sat Jun 19 08:58:18 EDT 2021
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords β-amyloid peptide
Alzheimer’s disease
phage display peptide
bifunctional nanoparticles
brain targeting
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a325t-eb7dae98ef530d5245dc1563823f271939185c1a09015ce396566a35d70433eb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5453-5882
PQID 2533319039
PQPubID 23479
PageCount 12
ParticipantIDs proquest_miscellaneous_2533319039
crossref_primary_10_1021_acschemneuro_1c00035
acs_journals_10_1021_acschemneuro_1c00035
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
7~N
VG9
3RI
GGK
W1F
ABFRP
ACS
AEESW
AFEFF
ABMVS
ABUCX
IH9
AQSVZ
ED~
UI2
PublicationCentury 2000
PublicationDate 20210616
2021-06-16
PublicationDateYYYYMMDD 2021-06-16
PublicationDate_xml – month: 06
  year: 2021
  text: 20210616
  day: 16
PublicationDecade 2020
PublicationTitle ACS chemical neuroscience
PublicationTitleAlternate ACS Chem. Neurosci
PublicationYear 2021
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref9/cit9
ref45/cit45
ref3/cit3
ref27/cit27
ref63/cit63
ref56/cit56
ref16/cit16
ref52/cit52
ref23/cit23
ref8/cit8
ref31/cit31
ref59/cit59
ref2/cit2
ref34/cit34
ref37/cit37
ref20/cit20
ref48/cit48
ref60/cit60
ref17/cit17
Rakonjac J. (ref46/cit46) 2011; 13
ref10/cit10
ref35/cit35
ref53/cit53
ref19/cit19
ref21/cit21
ref42/cit42
ref49/cit49
ref13/cit13
ref61/cit61
ref67/cit67
ref24/cit24
ref38/cit38
ref50/cit50
ref64/cit64
ref54/cit54
ref6/cit6
ref36/cit36
ref18/cit18
ref65/cit65
ref11/cit11
ref25/cit25
ref29/cit29
ref32/cit32
ref39/cit39
ref14/cit14
ref57/cit57
ref5/cit5
ref51/cit51
ref43/cit43
ref28/cit28
ref40/cit40
ref68/cit68
ref26/cit26
ref55/cit55
ref69/cit69
ref12/cit12
ref15/cit15
ref62/cit62
ref66/cit66
ref41/cit41
ref58/cit58
ref22/cit22
ref33/cit33
ref4/cit4
ref30/cit30
ref47/cit47
ref1/cit1
ref44/cit44
ref70/cit70
ref7/cit7
References_xml – ident: ref60/cit60
  doi: 10.3390/pharmaceutics10020040
– ident: ref57/cit57
  doi: 10.1111/j.1601-183X.2008.00453.x
– ident: ref21/cit21
  doi: 10.1016/j.jocn.2019.01.003
– ident: ref31/cit31
  doi: 10.1096/fj.05-5186fje
– ident: ref54/cit54
  doi: 10.1039/C9BM00676A
– ident: ref5/cit5
  doi: 10.3390/jcm9113452
– ident: ref39/cit39
  doi: 10.1007/s13238-019-0639-7
– ident: ref43/cit43
  doi: 10.1002/cmdc.200800273
– ident: ref48/cit48
  doi: 10.1007/s11095-010-0053-6
– ident: ref53/cit53
  doi: 10.1016/S0378-5173(01)00760-8
– ident: ref13/cit13
  doi: 10.1039/D0CC01551B
– ident: ref56/cit56
  doi: 10.1038/nrdp.2015.56
– ident: ref11/cit11
  doi: 10.1002/anie.200802808
– ident: ref37/cit37
  doi: 10.1016/S1389-0344(01)00087-9
– ident: ref45/cit45
  doi: 10.1271/bbb.110879
– ident: ref70/cit70
  doi: 10.1016/j.phymed.2020.153353
– ident: ref32/cit32
  doi: 10.1038/nbt1193
– ident: ref58/cit58
  doi: 10.1002/advs.201901165
– ident: ref14/cit14
  doi: 10.1038/s41582-018-0116-6
– ident: ref38/cit38
  doi: 10.1021/cr960065d
– ident: ref26/cit26
  doi: 10.3233/JAD-151024
– ident: ref1/cit1
  doi: 10.1016/j.cell.2019.09.001
– ident: ref30/cit30
  doi: 10.1016/j.jneumeth.2016.04.026
– ident: ref62/cit62
  doi: 10.1021/nn501292z
– ident: ref44/cit44
  doi: 10.1271/bbb.100388
– ident: ref27/cit27
  doi: 10.1038/380364a0
– ident: ref67/cit67
  doi: 10.1007/s10856-017-5859-x
– ident: ref63/cit63
  doi: 10.1016/j.npep.2015.06.008
– ident: ref18/cit18
  doi: 10.1016/j.biomaterials.2011.03.031
– ident: ref20/cit20
  doi: 10.1016/0006-8993(85)90963-1
– ident: ref2/cit2
  doi: 10.1016/j.ejphar.2017.09.043
– ident: ref25/cit25
  doi: 10.15252/emmm.201606666
– ident: ref61/cit61
  doi: 10.1016/j.jconrel.2018.05.011
– ident: ref68/cit68
  doi: 10.1016/j.ijpharm.2005.01.042
– ident: ref22/cit22
  doi: 10.1016/j.bbrep.2020.100792
– ident: ref24/cit24
  doi: 10.1007/s11095-013-1055-y
– ident: ref66/cit66
  doi: 10.3791/838
– ident: ref42/cit42
  doi: 10.1021/acsami.5b05606
– ident: ref15/cit15
  doi: 10.1111/jnc.15007
– ident: ref47/cit47
  doi: 10.1038/nm0202-121
– ident: ref3/cit3
  doi: 10.1016/j.phrs.2004.05.005
– ident: ref16/cit16
  doi: 10.1074/jbc.M113.537472
– ident: ref10/cit10
  doi: 10.1038/nrm2101
– ident: ref59/cit59
  doi: 10.4172/2161-0460.1000314
– ident: ref34/cit34
  doi: 10.1016/j.brainres.2016.01.028
– ident: ref8/cit8
  doi: 10.1038/emboj.2010.211
– ident: ref65/cit65
  doi: 10.1039/D0SC02212H
– ident: ref52/cit52
  doi: 10.1016/j.ijpharm.2019.02.012
– ident: ref19/cit19
  doi: 10.1021/acschembio.7b00087
– ident: ref23/cit23
  doi: 10.1016/j.neulet.2013.08.058
– ident: ref33/cit33
  doi: 10.1073/pnas.072027199
– ident: ref9/cit9
  doi: 10.1074/jbc.M111.264473
– ident: ref50/cit50
  doi: 10.1016/j.ejps.2011.11.015
– ident: ref12/cit12
  doi: 10.1002/adma.202006483
– ident: ref36/cit36
  doi: 10.1038/nn.3028
– ident: ref64/cit64
  doi: 10.1016/j.ebiom.2016.03.035
– ident: ref29/cit29
  doi: 10.1073/pnas.0436286100
– ident: ref35/cit35
  doi: 10.1073/pnas.1700407114
– ident: ref40/cit40
  doi: 10.1002/anie.202002783
– ident: ref4/cit4
  doi: 10.1002/psc.2789
– ident: ref51/cit51
  doi: 10.1007/s00726-011-0979-y
– ident: ref17/cit17
  doi: 10.1371/journal.pone.0147470
– volume: 13
  start-page: 51
  issue: 2
  year: 2011
  ident: ref46/cit46
  publication-title: Curr. Issues. Mol. Biol.
  contributor:
    fullname: Rakonjac J.
– ident: ref7/cit7
  doi: 10.1111/j.1365-2990.2010.01137.x
– ident: ref49/cit49
  doi: 10.1038/s41467-017-01096-0
– ident: ref6/cit6
  doi: 10.1007/s12035-017-0487-5
– ident: ref41/cit41
  doi: 10.3390/molecules25040874
– ident: ref55/cit55
  doi: 10.1007/s11095-013-1025-4
– ident: ref69/cit69
  doi: 10.1016/j.ejpb.2019.10.003
– ident: ref28/cit28
  doi: 10.1021/acschemneuro.0c00518
SSID ssj0069086
Score 2.3880696
Snippet Alzheimer’s disease (AD) is an insidious and progressive neurodegenerative disease with few disease-modifying treatments. A variety of peptide/protein drugs...
SourceID proquest
crossref
acs
SourceType Aggregation Database
Publisher
StartPage 2110
Title Brain Targeting and Aβ Binding Bifunctional Nanoparticles Inhibit Amyloid Protein Aggregation in APP/PS1 Transgenic Mice
URI http://dx.doi.org/10.1021/acschemneuro.1c00035
https://search.proquest.com/docview/2533319039
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1fS8MwEA86X3zx3xTnPyKI4EO3JW3X9rEbzilMB9tgbyVN0ll0nbjuYX4sP4ifyUvaolNEfWkplLRckrvf7-5yh9AZMz3JAbYajh1RICgMthSrM4MBGnWpwywRKX9H97bRGVo3I3v0QRS_RvApqTEONE9OdHnHKuE69rWK1qhKIlRQqNUvNC8QPd3ZEXi5aziATIqjcj-MogwSny0bpGV9rI1MexPdFUd1stySh-o8Dav85Xvlxj_-_xbayPEm9rMFso1WZLKDyn4CXHuywOdYZ4Bq13oZLZqqXwQe6ORwMGmYJQL7b6-4GeuzL3BXZjDzHmLQy0C487w6fJ3cx2GcYn-yeJzGAvdU_QcYzB8DoR_r6cfqsder9foEaxMJazfmuAuqahcN25eDVsfIWzMYzKR2asjQEUx6roxssy5satmCAxNUQcWIKtF7gAM4YXUFN7g0PQUbmWkLRxVMAwK_h0rJNJH7CFvS4pEdMguglEUiERKTsIiEHhVuI-RuBV2ACIN8a80CHTWnJPgs1yCXawUZxVwGT1m1jl_ePy0mPIBtpWIlLJHT-SygAINBO9VN7-Af3z9E61TlvKjeRo0jVEqf5_IYQEsanuiVCterEXkHsjLreQ
link.rule.ids 315,786,790,2782,27109,27957,27958,57093,57143
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT-MwEB4VOMCFx7Ir3nglhMQhpXbiJjmGClQWiipRVtwix3YggqaIpIfys_gh_CbGbrI8pBXiFCWKnNgez3yfZzwDsCfcUEuErY7PU4YEReCSEi3hCESjAfOFp1Kz39G7aHevvD_X_LoBvD4Lgz9RYEuFdeK_ZRegh_gMezG0WR6bVFoX2AzMcR8puUFEnctaASPfswUekZ4Hjo8ApT4x959WjF2SxUe79FEtW1tzsgR___2lDTG5a47LpCmfPiVw_HY3lmGxQp8kmorLCjR0_gNWoxyZ93BC9omNB7Ub7aswOTLVI8jAhoqjgSMiVyR6eSZHmT0Jg1djFKd7iQS1NNLvKsqOnOa3WZKVJBpO7keZIn2TDQIbi26Q3t9YYSDmtt8_7F9SYg0mSnImSQ8V10-4OjkedLpOVajBES7jpaMTXwkdBjrlbktx5nElkRcaF2PKzAyEiAokFS0DPqR2QwMihcuVb9KnIZ3_BbP5KNdrQDztyZQnwkNg5dFUJdSlIqVJyFTQTmSwDgc4hHG10IrY-tAZjd-Pa1yN6zo49ZTGD9PcHV-8_7ue9xgXmfGciFyPxkXMEBSjrmq54cY3vr8L891B7zw-P70424QFZqJhTNWj9hbMlo9jvY1wpkx2rPC-ArW48vM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Ra9swEBZbB2Mva9dsNOvaqTAGe3ASyVZsP7ppQ7s2wZAEwl6MLMmt6eKE2XlIf1Z_yH5T7xRnpIMxtidjY2RLOt19n-50R8gn6YZGAWx1fJFxICgSlpTsSEcCGg24Lz2d4X7HYNi9mHhfp2K6VeoLfqKElkrrxMdVvdBZnWGAteE59GRmMz22mLJusOfkhcAa3oiKeqONEgbOZ4s8AkUPHB9AyubU3B9aQdukyqe26alqtvamv0u-_fpTG2Zy11pWaUvd_5bE8b-6skde1yiURmuxeUOemWKfNKICGPhsRT9TGxdqN9wbZHWKVSTo2IaMg6GjstA0-vlAT3N7IgauaBzXe4oUtDXQ8Drajl4Wt3maVzSarb7Pc01jzAoBjUU3QPNvrFBQvI3jdjxi1BpOkOhc0QEosLdk0j8f9y6cumCDI10uKsekvpYmDEwm3I4W3BNaAT9EV2PGcRZCQAeKyQ6CEGXcEMGkdIX2MY0a0Pp3ZKeYF-aAUM94KhOp9ABgeSzTKXOZzFgach10UxU0yRcYwqRecGVifemcJdvjmtTj2iTOZlqTxTqHx1_eP9nMfQKLDT0osjDzZZlwAMegszpu-P4fvv-RvIzP-sn15fDqkLziGBSDxY-6H8hO9WNpjgDVVOmxld9HbZP1bQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brain+Targeting+and+A%CE%B2+Binding+Bifunctional+Nanoparticles+Inhibit+Amyloid+Protein+Aggregation+in+APP%2FPS1+Transgenic+Mice&rft.jtitle=ACS+chemical+neuroscience&rft.au=Zhang%2C+Xiancheng&rft.au=Zhang%2C+Xiaoyu&rft.au=Li%2C+You&rft.au=Zhong%2C+Manli&rft.date=2021-06-16&rft.eissn=1948-7193&rft.volume=12&rft.issue=12&rft.spage=2110&rft.epage=2121&rft_id=info:doi/10.1021%2Facschemneuro.1c00035&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1948-7193&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1948-7193&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1948-7193&client=summon